A dual role for PGLYRP1 in host defense and immune regulation during B. pertussis infection

This study reveals that *Bordetella pertussis* exploits the host protein PGLYRP1 to exert a dual role in infection, where it initially enhances antibacterial defense via NOD1 signaling but later dampens inflammation and impairs bacterial killing by selectively suppressing TREM-1 and NOD2 pathways, thereby uncovering a novel immune evasion strategy with implications for vaccine and therapeutic design.

The Gist

The Big Picture: A Double-Agent in the Body's Defense System

Imagine your body is a fortress, and Bordetella pertussis (the bacteria that causes whooping cough) is a sneaky invader trying to break in. Usually, we think of our immune system as a team of soldiers who just fight the enemy. But this paper reveals that one specific soldier, a protein called PGLYRP1, is actually a "double agent." It has two very different jobs depending on when it shows up and what it is holding.

The researchers discovered that PGLYRP1 doesn't just kill bacteria; it also acts like a volume knob for the body's inflammation, turning the noise down when things get too loud. However, the bacteria are smart enough to trick this volume knob.

---

The Two Faces of PGLYRP1

1. The Early Morning Guard (The Killer)

Time: Early in the infection (Day 4).
Role: The Bouncer.

When the bacteria first arrive, PGLYRP1 acts like a tough bouncer at a club. It jumps out of the white blood cells (neutrophils) and directly attacks the bacteria, killing them before they can take over.

• The Evidence: When the researchers removed PGLYRP1 from mice, the bacteria multiplied much faster in the early days. Without this "bouncer," the fortress was breached quickly.

2. The Late Night Peacemaker (The Regulator)

Time: Later in the infection (Day 7).
Role: The Noise-Canceling Headphones.

As the infection drags on, the body's immune system starts screaming (inflammation). This screaming causes damage to the lungs, even if the bacteria are dying. PGLYRP1 switches roles here. It stops the immune system from overreacting, acting like noise-canceling headphones to keep the "volume" of inflammation down.

• The Twist: While this sounds good, the researchers found that by calming the immune system down too much, PGLYRP1 actually helps the bacteria survive longer. It's like turning down the fire alarm so the fire department doesn't come, which lets the fire (the bacteria) burn longer.

---

The Bacteria's Magic Trick: The "Decoy"

How does Bordetella pertussis trick PGLYRP1? It uses a specific piece of its own armor called Tracheal Cytotoxin (TCT).

Think of PGLYRP1 as a security guard who looks for specific "bad guy" patterns on bacteria to decide whether to attack or calm down.

• Normal Bacteria (like Staph): They wear a heavy, bulky coat (complex cell wall). When PGLYRP1 sees this, it gets excited and sounds the alarm (TREM-1), causing a massive inflammatory response to kill the invader.
• Whooping Cough Bacteria (B. pertussis): They release a tiny, lightweight piece of their coat (TCT) into the air. This piece is a decoy.

When PGLYRP1 grabs this decoy (TCT), it gets confused. Instead of sounding the loud alarm, it thinks, "Oh, this is a small, harmless piece. Let's just chill and turn down the volume."

The Result: The bacteria release these decoys to trick PGLYRP1 into turning off the immune system's "kill switch" and "alarm system." This allows the bacteria to hide in plain sight and survive longer in the lungs.

---

The "Signal Switch" Analogy

To understand how this works inside the cells, imagine the immune system has two different radio channels:

1. Channel NOD1: A channel that listens for the specific "decoy" signal (TCT).
2. Channel NOD2: A channel that listens for the "heavy coat" signal and triggers a massive, aggressive attack.

PGLYRP1 acts as a DJ:

• When it holds the TCT decoy, it boosts the volume on Channel NOD1 (which is a quieter, less aggressive signal).
• At the same time, it mutes Channel NOD2 (the aggressive signal).

By doing this, PGLYRP1 ensures the body fights the bacteria gently rather than aggressively. The bacteria love this because a gentle fight is easier to survive than a total war.

---

Why Does This Matter?

This discovery changes how we view whooping cough and immune defense:

1. It's not just about killing: The bacteria aren't just hiding; they are actively hacking the body's communication system.
2. New Treatments: If we can stop the bacteria from releasing these decoys, or if we can force PGLYRP1 to ignore the decoy and sound the alarm, we might be able to clear the infection faster without damaging the lungs.
3. Vaccine Design: Understanding this "decoy" strategy could help scientists design better vaccines that teach the immune system to recognize the trick and fight back harder.

The Bottom Line

Bordetella pertussis is a master manipulator. It releases a specific chemical "decoy" that tricks our body's immune regulator (PGLYRP1) into turning down the volume on the attack. This allows the bacteria to survive longer, causing the prolonged, severe coughing fits we know as whooping cough. The solution might lie in teaching our immune system to see through the trick.

Technical Summary

1. Problem Statement

• Public Health Context: Bordetella pertussis (whooping cough) remains a significant public health threat despite vaccination, due to waning immunity and bacterial immune evasion.
• Scientific Gap: While Peptidoglycan Recognition Proteins (PGLYRPs) are known as bactericidal agents in mammals, their specific roles in immune signaling and modulation during Gram-negative infections (specifically B. pertussis) are poorly understood.
• Specific Mechanism: B. pertussis releases a unique peptidoglycan (PGN) fragment called Tracheal Cytotoxin (TCT), a monomeric disaccharide-tetrapeptide containing a 1,6-anhydro-MurNAc modification. Previous work suggested TCT dampens immune responses by skewing signaling toward NOD1 and away from NOD2, but the interplay between TCT, host PGLYRP1, and downstream inflammatory pathways (like TREM-1) was unclear.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, ex vivo assays, and advanced transcriptomics:

• Animal Models:
  • Strains: Wild-type (WT) and PGLYRP1-knockout (PGLYRP1 KO) BALB/c mice.
  • Infection: Intranasal infection with B. pertussis (WT, TCT-deficient, TCT-hyper-releasing, and polysaccharide-deficient strains).
  • Timepoints: Analysis at 4 days post-infection (DPI) and 7 DPI.
• Omics and Transcriptomics:
  • Bulk RNA-seq: Performed on lung homogenates to assess global gene expression and cytokine profiles.
  • Single-cell RNA-seq (scRNA-seq): Conducted on lung cells to map cell-type-specific expression of Pglyrp1, Nod1, Nod2, and Trem-1.
  • RNAscope: In situ hybridization to validate PGLYRP1 mRNA localization in lung tissue.
• Functional Assays:
  • Bactericidal Assays: In vitro killing of B. pertussis by bone marrow-derived neutrophils (BMDNs) and recombinant murine PGLYRP1 (mPGLYRP1).
  • Reporter Cell Assays: HEK293 cells expressing NOD1, NOD2, or TREM-1 reporters were stimulated with TCT, MDP, or conditioned media in the presence/absence of PGLYRP1 to measure NF-κB or NFAT activation.
  • Histopathology: H&E staining of lung sections to quantify inflammation (bronchovascular bundle formation and alveolar infiltration).

3. Key Contributions

The paper establishes a dual, temporally distinct role for PGLYRP1 in B. pertussis infection, acting as both a direct antimicrobial effector and a context-specific immunomodulator.

• Discovery of a "Decoy" Mechanism: The authors demonstrate that B. pertussis exploits the structural specificity of PGLYRP1. The unique structure of TCT (specifically the 1,6-anhydro-MurNAc) allows it to bind PGLYRP1 but fail to activate the pro-inflammatory TREM-1 pathway, unlike PGN from Gram-positive bacteria.
• Mechanistic Insight into NOD Signaling: The study clarifies that PGLYRP1 acts as a selective co-factor: it enhances NOD1 signaling (triggered by TCT) but suppresses NOD2 signaling (triggered by MDP).
• TREM-1 Regulation: The paper identifies a novel axis where TCT-bound PGLYRP1 complexes inhibit TREM-1 activation, thereby dampening the inflammatory cascade.

4. Key Results

A. Opposing Roles in Bacterial Burden (Time-Dependent)

• Early Infection (4 DPI): PGLYRP1 is protective. KO mice had significantly higher bacterial loads than WT mice. PGLYRP1 contributes to early bacterial control via direct bactericidal activity and neutrophil-mediated killing.
• Late Infection (7 DPI): PGLYRP1 becomes deleterious. KO mice had significantly lower bacterial loads than WT mice. This suggests that in the absence of PGLYRP1, the host mounts a more effective late-stage clearance, implying PGLYRP1 suppresses protective immunity later in infection.

B. Immunomodulation and Inflammation

• Reduced Pathology in KO Mice: PGLYRP1 KO mice exhibited significantly reduced lung immunopathology (less immune cell infiltration and bronchovascular damage) compared to WT mice.
• Cytokine Profile: Bulk RNA-seq of KO lungs showed upregulated pro-inflammatory cytokines (IL-6, IL-1β, IL-23, IL-36) and chemokines, and downregulated anti-inflammatory IL-10. This indicates PGLYRP1 normally dampens the inflammatory response.
• Role of TCT: The anti-inflammatory effect of PGLYRP1 was potentiated by TCT. Infection with TCT-deficient bacteria in KO mice resulted in even higher inflammation, suggesting TCT enhances PGLYRP1's ability to suppress inflammation.

C. Molecular Mechanisms

• NOD1 vs. NOD2 Skewing:
  • PGLYRP1 + TCT significantly enhanced NOD1 activation.
  • PGLYRP1 + MDP (NOD2 agonist) suppressed NOD2 activation.
  • scRNA-seq revealed that NOD1-expressing neutrophils have a less inflammatory profile (high Pla2g7, Tmsb4x) compared to NOD2-expressing neutrophils (high Il1a, Ccl3, Ptgs2).
• TREM-1 Inhibition:
  • PGN from S. aureus or B. subtilis (sacculus-derived) enhanced PGLYRP1-mediated TREM-1 activation.
  • TCT failed to support this activation and actually antagonized it. This prevents the amplification of NF-κB-driven inflammation via TREM-1.
• Bacterial Evasion:
  • B. pertussis surface polysaccharides (Bps operon) shield the bacteria from PGLYRP1-mediated killing.
  • The release of TCT acts as a decoy to bind PGLYRP1, skewing signaling toward NOD1 and away from NOD2/TREM-1, effectively "hijacking" the host's regulatory circuit to limit inflammation.

5. Significance and Implications

• Paradigm Shift: The study redefines mammalian PGLYRP1 from a simple bactericidal peptide to a sophisticated PGN-structure-specific immunomodulator. Its function depends entirely on the specific PGN fragment it encounters.
• Novel Evasion Strategy: B. pertussis does not just hide from the immune system; it actively manipulates it. By releasing TCT, the pathogen co-opts PGLYRP1 to suppress the potent NOD2/TREM-1 inflammatory pathways, promoting persistence and reducing immunopathology.
• Therapeutic Potential:
  • Host-Directed Therapy: Targeting the TCT–PGLYRP1–TREM-1 axis could attenuate severe inflammation (immunopathology) without compromising bacterial clearance.
  • Vaccine Design: Understanding how PGN structure influences immune signaling could inform the design of vaccines that elicit stronger NOD2-dependent memory responses rather than the dampened NOD1 responses currently induced by natural infection.
• Evolutionary Insight: This highlights an evolutionary arms race where pathogens evolve specific PGN structures to bias host innate sensors, turning a defense mechanism (PGLYRP1) into a tool for immune suppression.

In conclusion, the paper demonstrates that B. pertussis utilizes the unique structure of its secreted TCT to manipulate host PGLYRP1, creating a dual-edged sword: PGLYRP1 aids early bacterial killing but is subsequently co-opted to suppress the very inflammatory responses required for late-stage clearance.